<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005339</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0877</org_study_id>
    <nct_id>NCT04005339</nct_id>
  </id_info>
  <brief_title>NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer</brief_title>
  <official_title>NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the clinical activity of the combination of fluorouracil,&#xD;
      leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced&#xD;
      biliary tract cancers following gemcitabine and platinum chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open label, multicenter phase II study to evaluate the clinical&#xD;
      activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as&#xD;
      second-line treatment in patients with advanced biliary tract cancers following gemcitabine&#xD;
      and platinum chemotherapy. Patients with advanced biliary tract cancers who have adequate&#xD;
      performance status and adequate hepatic and renal function will be eligible. Patients may&#xD;
      have received adjuvant chemotherapy and/or radiation therapy prior to enrolling in the trial,&#xD;
      but a minimum of 6 months between adjuvant chemotherapy and this current therapy are&#xD;
      required. Patients may continue on study as long as they are tolerating treatment and do not&#xD;
      have progression of disease by RECIST v1.1 criteria. Response assessments will occur using&#xD;
      imaging (CT or MRI) every 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy of fluorouracil, leucovorin, and nanoliposomal irinotecan in advanced biliary tract cancers following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>4 months</time_frame>
    <description>Defined as positive if there is no evidence of disease progression (PD) at 4 months, as measured by RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of best overall response rate (ORR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of median progression-free survival (mPFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of median overall survival (mOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of median time to disease progression (mTTP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of disease control rate (DCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of median duration of disease control (DDC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The activity of fluorouracil, leucovorin, and nanoliposomal irinotecan in patients with advanced biliary tract cancers treated following progression on or intolerance of gemcitabine and platinum chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>Measured in terms of maximum change in tumor marker, CA19-9.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood for the analysis of circulating tumor DNA as a surrogate marker of disease burden.</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of dynamics of circulating tumor DNA change compared with change in CA19-9.</description>
  </other_outcome>
  <other_outcome>
    <measure>Archived tumor tissue using next-generation sequencing (NGS) and immunohistochemistry (IHC) in order to elucidate potential mutational biomarkers predictive of response to fluorouracil, leucovorin, and nanoliposomal irinotecan.</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation of tumor genetic mutations and protein expression levels with progression-free survival.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Advanced Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoliposomal Irinotecan</intervention_name>
    <description>Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 400 mg/ IV over 30 minutes, every 14 days.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Fluorouracil 2,400 mg/m IV over 46 hours.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically-confirmed biliary tract cancer (cholangiocarcinoma or gallbladder&#xD;
             adenocarcinoma), unresectable or metastatic&#xD;
&#xD;
          -  Disease progression on or intolerance of gemcitabine- and platinum-based chemotherapy&#xD;
&#xD;
          -  No more than 1 prior line of chemotherapy for unresectable or metastatic disease&#xD;
             (adjuvant therapy does not count)&#xD;
&#xD;
          -  Measurable disease by RECIST v1.1 criteria&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  HIV-positive patients are eligible provided: Stable HAART regimen, No concurrent&#xD;
             prophylactic antibiotics or antifungals, and CD4 count above 250 and undetectable&#xD;
             viral load&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, and renal function&#xD;
&#xD;
          -  Consent to access archived tumor tissue if available (available tissue is not required&#xD;
             for enrollment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ampullary adenocarcinoma&#xD;
&#xD;
          -  Woman who are pregnant or breastfeeding&#xD;
&#xD;
          -  Anti-cancer treatment within 3 weeks prior to enrollment&#xD;
&#xD;
          -  Prior irinotecan or nanoliposomal irinotecan&#xD;
&#xD;
          -  Central nervous system metastases unless stable for at least 4 weeks and at least 2&#xD;
             weeks off corticosteroids&#xD;
&#xD;
          -  Exposure to a strong CYP3A4 inducer, strong CYP3A4 inhibitor, or strong UGT1A1&#xD;
             inhibitor within 2 weeks of study start&#xD;
&#xD;
          -  Known concurrent malignancy or other malignancy within 3 years except for&#xD;
             non-melanomatous skin cancers, prostate or cervical cancers following curative&#xD;
             therapy, or superficial bladder cancer&#xD;
&#xD;
          -  Bowel obstruction&#xD;
&#xD;
          -  Allergy or hypersensitivity to fluoropyrimidines, irinotecan, or nanoliposomal&#xD;
             irinotecan&#xD;
&#xD;
          -  Clinically significant liver disease: Patients with resolved hepatitis B infection are&#xD;
             eligible if HBsAg testing is negative; Patients with resolved hepatitis C infection&#xD;
             are eligible if viral RNA PCR is negative&#xD;
&#xD;
          -  Severe infections within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Weinberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center, Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael Meirovich</last_name>
      <phone>202-687-9861</phone>
      <email>ym419@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Martinez</last_name>
      <phone>317-274-3502</phone>
      <email>maimart@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Anita Turk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine- Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Brodbeck</last_name>
      <phone>314-747-8085</phone>
      <email>bkelsey@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Katrina Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Biliary Tract Cancer</keyword>
  <keyword>Biliary Tract Cancer</keyword>
  <keyword>GI Cancer</keyword>
  <keyword>Biliary Cancer</keyword>
  <keyword>NAPOLI-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

